181 related articles for article (PubMed ID: 37818374)
1. Extracellular vesicles derived from immortalized human natural killer cell line NK3.3 as a novel therapeutic for multiple myeloma.
Matchett EC; Kornbluth J
Front Immunol; 2023; 14():1265101. PubMed ID: 37818374
[TBL] [Abstract][Full Text] [Related]
2. Extracellular Vesicles From the Human Natural Killer Cell Line NK3.3 Have Broad and Potent Anti-Tumor Activity.
Cochran AM; Kornbluth J
Front Cell Dev Biol; 2021; 9():698639. PubMed ID: 34368150
[TBL] [Abstract][Full Text] [Related]
3. A clinically relevant large-scale biomanufacturing workflow to produce natural killer cells and natural killer cell-derived extracellular vesicles for cancer immunotherapy.
St-Denis-Bissonnette F; Cummings SE; Qiu S; Stalker A; Muradia G; Mehic J; Mediratta K; Kaczmarek S; Burger D; Lee SH; Wang L; Lavoie JR
J Extracell Vesicles; 2023 Dec; 12(12):e12387. PubMed ID: 38054534
[TBL] [Abstract][Full Text] [Related]
4. Enhancement of antitumor potency of extracellular vesicles derived from natural killer cells by IL-15 priming.
Zhu L; Kalimuthu S; Oh JM; Gangadaran P; Baek SH; Jeong SY; Lee SW; Lee J; Ahn BC
Biomaterials; 2019 Jan; 190-191():38-50. PubMed ID: 30391801
[TBL] [Abstract][Full Text] [Related]
5. Cross-Dressing of Multiple Myeloma Cells Mediated by Extracellular Vesicles Conveying MIC and ULBP Ligands Promotes NK Cell Killing.
Vulpis E; Loconte L; Cassone C; Antonangeli F; Caracciolo G; Masuelli L; Fazio F; Petrucci MT; Fionda C; Soriani A; Cerboni C; Cippitelli M; Santoni A; Zingoni A
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298418
[TBL] [Abstract][Full Text] [Related]
6. Immunoregulatory functions and therapeutic potential of natural killer cell-derived extracellular vesicles in chronic diseases.
He S; Su L; Hu H; Liu H; Xiong J; Gong X; Chi H; Wu Q; Yang G
Front Immunol; 2023; 14():1328094. PubMed ID: 38239346
[TBL] [Abstract][Full Text] [Related]
7. Natural killer cell lines preferentially kill clonogenic multiple myeloma cells and decrease myeloma engraftment in a bioluminescent xenograft mouse model.
Swift BE; Williams BA; Kosaka Y; Wang XH; Medin JA; Viswanathan S; Martinez-Lopez J; Keating A
Haematologica; 2012 Jul; 97(7):1020-8. PubMed ID: 22271890
[TBL] [Abstract][Full Text] [Related]
8. Large-scale isolation and cytotoxicity of extracellular vesicles derived from activated human natural killer cells.
Jong AY; Wu CH; Li J; Sun J; Fabbri M; Wayne AS; Seeger RC
J Extracell Vesicles; 2017; 6(1):1294368. PubMed ID: 28326171
[TBL] [Abstract][Full Text] [Related]
9. Natural Killer Cell-Derived Extracellular Vesicles as a Promising Immunotherapeutic Strategy for Cancer: A Systematic Review.
Chan AML; Cheah JM; Lokanathan Y; Ng MH; Law JX
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835438
[TBL] [Abstract][Full Text] [Related]
10. Proteome Analysis of Human Natural Killer Cell Derived Extracellular Vesicles for Identification of Anticancer Effectors.
Choi JW; Lim S; Kang JH; Hwang SH; Hwang KC; Kim SW; Lee S
Molecules; 2020 Nov; 25(21):. PubMed ID: 33182448
[TBL] [Abstract][Full Text] [Related]
11. Extracellular vesicles derived from natural killer cells use multiple cytotoxic proteins and killing mechanisms to target cancer cells.
Wu CH; Li J; Li L; Sun J; Fabbri M; Wayne AS; Seeger RC; Jong AY
J Extracell Vesicles; 2019; 8(1):1588538. PubMed ID: 30891164
[TBL] [Abstract][Full Text] [Related]
12. Myeloma-derived extracellular vesicles mediate HGF/c-Met signaling in osteoblast-like cells.
Strømme O; Psonka-Antonczyk KM; Stokke BT; Sundan A; Arum CJ; Brede G
Exp Cell Res; 2019 Oct; 383(1):111490. PubMed ID: 31283912
[TBL] [Abstract][Full Text] [Related]
13. NK3.3-Derived Extracellular Vesicles Penetrate and Selectively Kill Treatment-Resistant Tumor Cells.
McCune A; Kornbluth J
Cancers (Basel); 2023 Dec; 16(1):. PubMed ID: 38201518
[TBL] [Abstract][Full Text] [Related]
14. Natural Killer Cell-Derived Extracellular Vesicles: Novel Players in Cancer Immunotherapy.
Wu F; Xie M; Hun M; She Z; Li C; Luo S; Chen X; Wan W; Wen C; Tian J
Front Immunol; 2021; 12():658698. PubMed ID: 34093547
[TBL] [Abstract][Full Text] [Related]
15. Secreted Ligands of the NK Cell Receptor NKp30: B7-H6 Is in Contrast to BAG6 Only Marginally Released via Extracellular Vesicles.
Ponath V; Hoffmann N; Bergmann L; Mäder C; Alashkar Alhamwe B; Preußer C; Pogge von Strandmann E
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33671836
[TBL] [Abstract][Full Text] [Related]
16. NK cell therapy in relapsed refractory multiple myeloma.
Roshandel E; Ghaffari-Nazari H; Mohammadian M; Salimi M; Abroun S; Mirfakhraie R; Hajifathali A
Clin Immunol; 2023 Jan; 246():109168. PubMed ID: 36415020
[TBL] [Abstract][Full Text] [Related]
17. Comparison of characteristics and tumor targeting properties of extracellular vesicles derived from primary NK cells or NK-cell lines stimulated with IL-15 or IL-12/15/18.
Aarsund M; Segers FM; Wu Y; Inngjerdingen M
Cancer Immunol Immunother; 2022 Sep; 71(9):2227-2238. PubMed ID: 35119498
[TBL] [Abstract][Full Text] [Related]
18. [Progress in Chimeric Antigen Receptor-Modified Natural Killer Cells for Multiple Myeloma].
Tang WJ; Li Y; Zheng YH; Zhang L; Niu T
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2023 Apr; 45(2):290-297. PubMed ID: 37157078
[TBL] [Abstract][Full Text] [Related]
19. NKG2A and circulating extracellular vesicles are key regulators of natural killer cell activity in prostate cancer after prostatectomy.
Lu YC; Ho CH; Hong JH; Kuo MC; Liao YA; Jaw FS; Cheng JC; Huang CY; Chang KP; Chen CH; Lin JA; Hsiao A; Kung HN
Mol Oncol; 2023 Aug; 17(8):1613-1627. PubMed ID: 36931723
[TBL] [Abstract][Full Text] [Related]
20. Cancer Immunotherapy Based on Natural Killer Cells: Current Progress and New Opportunities.
Hu W; Wang G; Huang D; Sui M; Xu Y
Front Immunol; 2019; 10():1205. PubMed ID: 31214177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
